Accium BioSciences and CMIC Announce Strategic Alliance

Accium BioSciences, Inc. and CMIC Co., Ltd. have announced a partnership to offer Exploratory-IND (microdosing) and low-radiation PK/ADME clinical trials services to Japan pharmaceutical clients.

Accium offers ultra-sensitive AMS bioanalysis and a network of clinical and regulatory providers to reduce the time and cost of drug development. Under the terms of this agreement, CMIC will integrate Accium’s service package for Japanese clients.

“This partnership leverages Accium’s unique bioanalytical and clinical trials capabilities with CMIC’s proven value creating clinical development processes. CMIC is recognized as the trusted source for clinical development services in Japan. Together our companies provide seamless access to the tools described in FDA’s recent Exploratory-IND Guidance,” stated Michael Chansler, Director of Business Development for Accium.

“Clinical studies conducted within the CMIC/Accium framework will provide the benefits of conducting trials to U.S. FDA standards while preserving Japanese drug development requirements.”

“There is a growing interest among Japanese pharmaceutical researchers to implement time and cost saving strategies in drug development. The Exploratory IND Guidance recently issued by the U.S. FDA under their ‘Critical Path Initiative’ combined with recently developed Accelerator Mass Spectrometry techniques offered by Accium open new opportunities for cost saving to the Japanese drug developers,” said Kazuo Nakamura, President & CEO of CMIC.

 “Accium and CMIC have been in discussion for some time to develop an effective partnering plan that will help our clients take advantage of these new tools for drug development. We are pleased to offer Accium’s services and partner network to the Japan pharmaceutical industry.”